Addendum
Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110
Report documents
-
Addendum
Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110
Dossier assessment
In combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia who are FMS-like tyrosine kinase 3 mutation-positive
Unchanged after addendum: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2024-05-02 A G-BA decision was published.
Project details
- Project no.
- A24-34
- Commission
- Commission awarded on 27.03.2024 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A24-34_en
Connected Projects
-
Dossier assessment
Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed